抗IL-6抗体(Anti-IL-6, Human, Goat-Poly antibody)

• 価格
• Product Details
• Applications and Data
• Related Product & Information
• Citations

価格

目次に戻る

Product Details

Species Reactivity	Human
Label	Unconjugated
Immunogen	E. coli-derived recombinant human IL-6Pro29-Met212Accession # P05231
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Specificity	Detects human IL-6 in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant mouse IL-6 is observed.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Immunocytochemistry	5-15 µg/mL	See below
Neutralization	Measured by its ability to neutralize IL‑6-induced proliferation in the T1165.85.2.1 mouse plasmacytoma cell line. Nordan, R.P. and M. Potter (1986) Science 233:566. The Neutralization Dose (ND50) is typically 15-45 ng/mL in the presence of 2.5 ng/mL Recombinant Human IL‑6.

Immunocytochemistry
	IL‑6 in Human PBMCs. IL‑6 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) treated with LPS and monensin using Goat Anti-Human IL‑6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-206-NA) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counter­stained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Neutralization
	Cell Proliferation Induced by IL‑6 and Neutralization by Human IL‑6 Antibody. Recombinant Human IL‑6 (Catalog # 206-IL) stimulates proliferation in the T1165.85.2.1 mouse plasmacytoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human IL‑6 (2.5 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-206-NA). The ND50 is typically 15-45 ng/mL.

目次に戻る

Related Product & Information

Long Name	Interleukin 6
Entrez Gene IDs	3569 (Human); 16193 (Mouse); 24498 (Rat); 399500 (Porcine); 280826 (Bovine); 403985 (Canine); 100034196 (Equine); 493687 (Feline); 100008733 (Rabbit)
Background	IL-6
background_content	Background: IL-6 Interleukin 6 (IL-6) is a pleiotropic alpha -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is essential for the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22-28 kDa phosphorylated and variably glycosylated molecule (1-4). Mature human IL-6 is 183 amino acids (aa) in length and shares 41% aa sequence identity with mouse and rat IL-6 (5). Alternate splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties (6-9). Human IL-6 is equally active on mouse and rat cells (10). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (11). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (12). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL-6 R (3). Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 13).

目次に戻る

Citations

1. Improved efficiency of in situ protein analysis by proximity ligation using UnFold probes
   Authors: A Klaesson, K Grannas, T Ebai, J Heldin, B Koos, M Leino, D Raykova, J Oelrich, L Arngården, O Söderberg, U Landegren
   Sci Rep, 2018;8(1):5400.
   Species: Human
   Sample Type: Recombinant Protein
   Application: Proximity Ligation Assay


2. Streamlined circular proximity ligation assay provides high stringency and compatibility with low-affinity antibodies
   Authors: R Jalili, J Horecka, JR Swartz, RW Davis, HHJ Persson
   Proc. Natl. Acad. Sci. U.S.A., 2018;0(0):.
   Application: Affinity Assay


3. SorLA in interleukin-6 signaling and turnover
   Authors: JV Larsen, CM Petersen
   Mol. Cell. Biol, 2017;0(0):.
   Species: Human
   Sample Type: Whole Cells
   Application: ICC


4. Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway
   Authors: B Kim, HS Kim, S Kim, G Haegeman, BK Tsang, DN Dhanasekar, YS Song
   Cancer Res Treat, 2017;49(2):338-349.
   Species: Human
   Sample Type: Whole Cells
   Application: Neut


5. Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ
   Authors: M Sameni, D Cavallo-Me, OE Franco, A Chalasani, K Ji, N Aggarwal, A Anbalagan, X Chen, RR Mattingly, SW Hayward, BF Sloane
   Breast Cancer Res., 2017;19(1):56.
   Species: Human
   Sample Type: Whole Cells
   Application: Neut


6. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation.
   Authors: Procopio M, Laszlo C, Al Labban D, Kim D, Bordignon P, Jo S, Goruppi S, Menietti E, Ostano P, Ala U, Provero P, Hoetzenecker W, Neel V, Kilarski W, Swartz M, Brisken C, Lefort K, Dotto G
   Nat Cell Biol, 2015;17(9):1193-204.
   Species: Human
   Sample Type: Cell Lysates
   Application: WB


7. Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration.
   Authors: Osuala K, Sameni M, Shah S, Aggarwal N, Simonait M, Franco O, Hong Y, Hayward S, Behbod F, Mattingly R, Sloane B
   BMC Cancer, 2015;15(0):584.
   Species: Human
   Sample Type: Whole Cells
   Application: Neut


8. Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
   Authors: Wang H, Cui X, Goodin S, Ding N, Van Doren J, Du Z, Huang M, Liu Y, Cheng X, Dipaola R, Conney A, Zheng X
   Oncol Rep, 2014;31(2):835-41.
   Species: Human
   Sample Type: Whole Cells
   Application: ICC


9. Tumor-activated TCRgammadelta(+) T cells from gastric cancer patients induce the antitumor immune response of TCRalphabeta(+) T cells via their antigen-presenting cell-like effects.
   Authors: Mao C, Mou X, Zhou Y, Yuan G, Xu C, Liu H, Zheng T, Tong J, Wang S, Chen D
   J Immunol Res, 2014;2014(0):593562.
   Species: Human
   Sample Type: Whole Cells
   Application: Functional Assay


10. Digital microfluidic assay for protein detection.
    Authors: Mok J, Mindrinos M, Davis R, Javanmard M
    Proc Natl Acad Sci U S A, 2014;111(6):2110-5.
    Species: Human
    Sample Type: Recombinant Protein
    Application: Microfluidic Assay

目次に戻る